Article

Life Sciences

Life Sciences companies continue to respond to a changing global landscape, and strive to pursue innovative solutions to address today's challenges. The DTTL network understands the complexity of these challenges, and works with clients worldwide to drive progress and bring discoveries to life.

2018 Global life sciences outlook

With the evolving industrialization of life sciences, companies need to embrace the exponential changes in technology to change the way they work, conduct research, innovate, manufacture and distribute products, and meet consumer expectations.

Innovating life sciences in the fourth industrial revolution: Embrace, build, grow

open in new window Find out more

A new future for R&D?

The pharmaceutical industry continues to face an extremely challenging R&D environment and has yet to turn a corner in terms of its R&D value proposition. Despite this, the Deloitte UK's report presents an optimistic road ahead for R&D and business leaders, exploring the emerging technologies that have the potential to dramatically transform the productivity and efficiency by which drugs are discovered, developed and brought to patients.

Measuring the return from pharmaceutical innovation 2017

open in new window Find out more

Pharma and the connected patient

With over 260,000 health apps worldwide and 70% of patient groups using at least one app to manage their condition, it’s clear that a digital ecosystem has developed within healthcare. New research released by the Deloitte Centre for Health Solutions explores how digital technology can help pharma embrace patient centricity to remain relevant, profitable, and to deliver better health outcomes.

How digital technology is enabling patient centricity

open in new window Find out more

2017 Pharmaceutical R&D leader survey

In an environment driven by scientific, regulatory and economic pressure, Deloitte Centre for Health Solutions’ first annual Pharmaceutical R&D leader survey gauges the current sentiment of R&D executives. Based on interviews with R&D leaders across a sample of big pharma organisations, the report identifies current priorities, future investment plans and key factors that are driving operational excellence.

Innovating to survive, collaborating to thrive

open in new window Find out more

Related topics